Back to UBS Group AG UBS Group AG

BTAIBTAI
Showing 8 of 30 quarters

Position history for UBS Group AGUBS Group AG's holdings in BIOXCEL THERAPEUTICS INC

UBS Group AG holds 158,065 shares of BTAI (BIOXCEL THERAPEUTICS INC), worth $222,871 as of 2026-Q2. The position was increased (+199.4% shares).

Current Value

$222,871

Current Shares

158,065

Total Value Change

+$214,802

Total Shares Change

+144,837

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
158,065
+199.4%
$222,8710.0%$1.41
25
2026-Q1
Increased
52,788
+37.7%
$70,7360.0%$1.60
19
2025-Q4
Decreased
38,340
-11.9%
$61,3440.0%$1.53
0
2025-Q3
Increased
43,542
+9.2%
$111,4680.0%$2.62
16
2025-Q2
Decreased
39,882
-60.8%
$72,1870.0%$1.77
0
2025-Q1
Decreased
101,778
-92.0%
$206,6090.0%$2.12
0
2024-Q4
Increased
1.3M
+9553.0%
$477,5580.0%$5.87
39
2024-Q3
Decreased
13,228
-74.8%
$8,0690.0%$9.65
0

Other major holders of BTAI: BNP PARIBAS FINANCIAL MARKETS, ADAGE CAPITAL PARTNERS GP, L.L.C., CITADEL ADVISORS LLC, ALLIANCEBERNSTEIN L.P.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used